Statins: a repurposed drug to fight cancer
W Jiang, JW Hu, XR He, WL Jin, XY He - Journal of Experimental & …, 2021 - Springer
As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol
and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of …
and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of …
Cancer metabolism: a therapeutic perspective
UE Martinez-Outschoorn, M Peiris-Pagés… - Nature reviews Clinical …, 2017 - nature.com
Awareness that the metabolic phenotype of cells within tumours is heterogeneous—and
distinct from that of their normal counterparts—is growing. In general, tumour cells …
distinct from that of their normal counterparts—is growing. In general, tumour cells …
[HTML][HTML] Pleiotropic effects of statins: A focus on cancer
Abstract The statin drugs ('statins') potently inhibit hydroxymethylglutaryl-coenzyme A (HMG-
CoA) reductase by competitively blocking the active site of the enzyme. Statins decrease de …
CoA) reductase by competitively blocking the active site of the enzyme. Statins decrease de …
[HTML][HTML] The role of lipid metabolic reprogramming in tumor microenvironment
K Yang, X Wang, C Song, Z He, R Wang, Y Xu… - Theranostics, 2023 - ncbi.nlm.nih.gov
Metabolic reprogramming is one of the most important hallmarks of malignant tumors.
Specifically, lipid metabolic reprogramming has marked impacts on cancer progression and …
Specifically, lipid metabolic reprogramming has marked impacts on cancer progression and …
Targeting lipid metabolism in liver cancer
M Alannan, H Fayyad-Kazan, V Trézéguet… - Biochemistry, 2020 - ACS Publications
Cancer cells are highly dependent on different metabolic pathways for sustaining their
survival, growth, and proliferation. Lipid metabolism not only provides the energetic needs of …
survival, growth, and proliferation. Lipid metabolism not only provides the energetic needs of …
Current and emerging uses of statins in clinical therapeutics: a review
JT Davies, SF Delfino, CE Feinberg… - Lipid …, 2016 - journals.sagepub.com
Statins, a class of cholesterol-lowering medications that inhibit 3-hydroxy-3-methyl-glutaryl-
coenzyme A reductase, are commonly administered to treat atherosclerotic cardiovascular …
coenzyme A reductase, are commonly administered to treat atherosclerotic cardiovascular …
Statin use and the risk of hepatocellular carcinoma: a meta-analysis of observational studies
Background and Aims: Statins are the first-line medication to treating hypercholesterolemia.
Several studies have investigated the impact of statins on the risk of hepatocellular …
Several studies have investigated the impact of statins on the risk of hepatocellular …
The effect of statins on cancer cells
L Matusewicz, J Meissner, M Toporkiewicz, AF Sikorski - Tumor Biology, 2015 - Springer
Abstract Statins [3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase,
abbreviated HMGCR) inhibitors], are well-known cholesterol-depleting agents. Since the …
abbreviated HMGCR) inhibitors], are well-known cholesterol-depleting agents. Since the …
Metabolism within the tumor microenvironment and its implication on cancer progression: An ongoing therapeutic target
MC Ocaña, B Martínez‐Poveda… - Medicinal research …, 2019 - Wiley Online Library
Since reprogramming energy metabolism is considered a new hallmark of cancer, tumor
metabolism is again in the spotlight of cancer research. Many studies have been carried out …
metabolism is again in the spotlight of cancer research. Many studies have been carried out …
Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1
M Juneja, D Kobelt, W Walther, C Voss, J Smith… - PLoS …, 2017 - journals.plos.org
MACC1 (Metastasis Associated in Colon Cancer 1) is a key driver and prognostic biomarker
for cancer progression and metastasis in a large variety of solid tumor types, particularly …
for cancer progression and metastasis in a large variety of solid tumor types, particularly …